Why the study?
Do beta-adrenoreceptor blocking agents improve symptoms in patients with angina pectoris and essential hypertension?
Do beta-adrenoreceptor blocking agents improve symptoms in patients with angina pectoris and essential hypertension?
Beta-blockers are valuable therapeutic agents for managing angina pectoris and essential hypertension by reducing myocardial oxygen requirements.
Supports beta-blocker use for angina symptom control; leaves open optimal agents and combinations versus contemporary therapies.
During the past decade, beta-adrenoreceptor blocking agents have proved to be valuable assets in our therapeutic armamentarium for management of both angina pectoris and essential hypertension. In ischemic heart disease, these agents reduce myocardial oxygen requirements by decreasing the force of myocardial contraction and by reducing heart rate. Consequently, decreased blood supply to portions of the myocardium is tolerated better. The beta-blockers are effective in reducing the frequency and severity of episodes of angina pectoris and in extending exercise tolerance. If needed, additional benefit may be gained by adding long-acting nitrates, or calcium-channel blockers or both.
No takes yet. Share an insight, caveat, or question.
T. N. Caris (1986) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: